The Resmed (ASX: RMD) share price is up 2% after the healthcare business announced its FY25 quarterly update.
Resmed is an ASX healthcare share involved in sleep and respiratory care, particularly sleep apnea and COPD.
FY25 fourth quarter performance
The company reported that in the three months to 30 June 2025 it reported:
- Revenue rose 10% to US$1.35 billion
- Underlying operating net profit increased 19% to US$476.4 million
- Operating net profit grew 19% to US$454.5 million
- Underlying net profit surged 22% to US$374.5 million
- Net profit jumped 30% to US$379.7 million
The business’ revenue was driven by increased demand for its sleep devices and masks portfolio, as well as solid growth across its residential care software business.
It benefited from rising profit margins, thanks to procurement, manufacturing and logistics efficiencies.
The business also declared a quarterly cash dividend of US$0.60 per share.
Resmed’s FY25 numbers
The company reported that in the three months to 30 June 2025 it reported:
- Revenue rose 10% to US$5.15 billion
- Underlying operating net profit increased 19% to US$1.76 billion
- Operating net profit grew 28% to US$1.68 billion
- Underlying net profit surged 23% to US$1.41 billion
- Net profit jumped 37% to US$1.4 billion
Management comments
The Resmed Chair and CEO Mick Farrell said:
Our strong finish to fiscal year 2025 reflects ongoing momentum across our business, driven by robust global demand for our market-leading sleep and breathing health devices, as well as our expanding digital health ecosystem.
In the fourth quarter, we delivered 10% headline revenue growth, 230 basis points in non-GAAP gross margin expansion, and 23% non-GAAP EPS growth. These results are a testament to the value that our best-in-class solutions deliver to our customers, and the unwavering dedication of our global team. Our connected care platform continues to set the standard for digital health innovation, empowering millions of people to take control of their sleep and breathing health with hardware, software and healthcare solutions delivered in their own homes.
As we move into fiscal year 2026, we will continue to invest in innovation, scale our digital health capabilities, and partner with patients, providers, payers, and policymakers to ensure more people around the world have access to the care they need to sleep better, breathe better, and live longer and healthier lives.
Final thoughts on the Resmed share price
The business seems to be doing well despite all of the uncertainty and it will hopefully be able perform for shareholders even if there are further changes in the US. But, I’m uncertain on ASX healthcare shares that have a significant presence in the US because of how tariffs could change things.
